A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
- Conditions
- Interventions
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Celgene
- Target Recruit Count
- 317
- Registration Number
- NCT00774345
- Locations
- 🇺🇸
Pacific Coast Hematology Oncology, Fountain Valley, California, United States
🇺🇸Memorial Hospital, Hollywood, Florida, United States
🇺🇸The Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
Trial of Romidepsin and Bortezomib for Multiple Myeloma
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 32
- Registration Number
- NCT00765102
- Locations
- 🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States
🇺🇸Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara, California, United States
🇺🇸Desert Cancer Care, Inc, Rancho Mirage, California, United States
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 31
- Registration Number
- NCT00761722
- Locations
- 🇺🇸
California Cancer Care Inc, Greenbrae, California, United States
🇺🇸Main Cancer Centers of Florida, P.A., Ocoee, Florida, United States
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Celgene
- Target Recruit Count
- 30
- Registration Number
- NCT00747123
- Locations
- 🇷🇺
Investigative Site, Saint-Petersburg, Russian Federation
A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial
- First Posted Date
- 2008-08-19
- Last Posted Date
- 2018-12-13
- Lead Sponsor
- Celgene
- Target Recruit Count
- 134
- Registration Number
- NCT00737529
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Tower Cancer Research Foundation, Los Angeles, California, United States
Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 7
- Registration Number
- NCT00717522
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸Kootenai Cancer Center, Coeur d'Alene, Idaho, United States
🇺🇸Nebraska Methodist Hospital, Omaha, Nebraska, United States
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1623
- Registration Number
- NCT00689936
- Locations
- 🇺🇸
Cedar Sinai Medical Center Dept of Medicine, Los Angeles, California, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
- Conditions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 33
- Registration Number
- NCT00688415
- Locations
- 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Scottsdale Healthcare, Scottsdale, Arizona, United States
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 22
- Registration Number
- NCT00667082
- Locations
- 🇦🇺
The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
🇦🇺Sir Charles Gairdner Hospital and University of Western Australia, Nedlands, Western Australia, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 400
- Registration Number
- NCT00657488
- Locations
- 🇧🇪
Hopital St Joseph, Gilly, Belgium
🇫🇷Chu D'Angers - Medecine D, Angers, France
🇫🇷Centre Hospitalier Du Dr Duschene - Hematologie, Boulogne Sur Mer, France